Moleculera Biosciences

Moleculera Biosciences is a commercial-stage precision medicine diagnostics company founded in 2012 and headquartered in Oklahoma City. The company's core offering is the Autoimmune Brain Panel™, a series of blood tests that helps clinicians diagnose immune-mediated neuropsychiatric disorders. Moleculera is leveraging its integrated technology platform—comprising diagnostic panels, a curated biorepository, and a biomarker discovery program—to expand into cardiovascular and Alzheimer's disease markets, addressing significant unmet needs in chronic, treatment-resistant conditions.

Integrated platform comprising 1) blood-based autoantibody testing panels (using cell-based assays/ELISAs), 2) a curated, longitudinal biorepository with linked clinical data, and 3) a biomarker discovery and therapeutic target identification program.

Moleculera appears to be a first-mover with the only commercially available comprehensive autoantibody panel for neuropsychiatric disorders. Potential competitors include university hospital labs offering single-analyte tests and large reference labs (e.g., Quest, LabCorp) that could eventually develop similar panels. Its defensibility lies in its integrated platform, curated biobank, and specialized clinical expertise.